Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8(1):402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM. Blocking IL-17: a promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci. 2020;21(19):7100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Wang L, Moore BB, et al. IL-17: balancing protective immunity and pathogenesis. J Immunol Res. 2023;2023:3360310.

Article  PubMed  PubMed Central  Google Scholar 

Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23(1):38–54.

Article  CAS  PubMed  Google Scholar 

Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731–41.

Article  CAS  PubMed  Google Scholar 

Karbach S, Croxford AL, Oelze M, et al. Interleukin-17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658–68.

Article  CAS  PubMed  Google Scholar 

Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445–56.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. Cosentyx. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761349. Accessed October 2024.

European Medicines Agency. Cosentyx. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx. Accessed October 2024.

ClinicalTrials.gov. NCT04930094. 2024. https://clinicaltrials.gov/study/NCT04930094. Accessed July 2024.

ClinicalTrials.gov. NCT05767034. 2024. https://clinicaltrials.gov/study/NCT05767034. Accessed July 2024.

ClinicalTrials.gov. NCT05380453. 2024. https://clinicaltrials.gov/study/NCT05380453. Accessed July 2024.

U.S. Food and Drug Administration. Taltz. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521. Accessed October 2024.

European Medicines Agency. Taltz. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz. Accessed October 2024.

European Medicines Agency. Kyntheum. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum. Accessed October 2024.

U.S. Food and Drug Administration. Siliq. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761032. Accessed October 2024.

ClinicalTrials.gov. NCT03957681. 2024. https://clinicaltrials.gov/study/NCT03957681. Accessed September 2024.

U.S. Food and Drug Administration. Bimzelx. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761151. Accessed October 2024.

European Medicines Agency. Bimzelx. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx. Accessed October 2024.

ClinicalTrials.gov. NCT05623345. 2024. https://clinicaltrials.gov/study/NCT05623345. Accessed September 2024.

U.S. Food and Drug Administration. Stelara. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761044. Accessed October 2024.

European Medicines Agency. Stelara. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara. Accessed October 2024.

U.S. Food and Drug Administration. Tremfya. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061. Accessed October 2024.

European Medicines Agency. Tremfya. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya. Accessed October 2024.

U.S. Food and Drug Administration. Ilumya. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067. Accessed October 2024.

European Medicines Agency. Ilumetri. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri. Accessed October 2024.

ClinicalTrials.gov. NCT04314544. 2024. https://clinicaltrials.gov/study/NCT04314544. Accessed September 2024.

ClinicalTrials.gov. NCT04991116. 2024. https://clinicaltrials.gov/study/NCT04991116. Accessed September 2024.

ClinicalTrials.gov. NCT04314531. 2024. https://clinicaltrials.gov/study/NCT04314531. Accessed September 2024.

U.S. Food and Drug Administration. Skyrizi. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105. Accessed October 2024.

European Medicines Agency. Skyrizi. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi. Accessed October 2024.

McInnes IB, Coates LC, Mease PJ, et al. OP0195 Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody®, in patients with active psoriatic arthritis (PSA): results from the global, randomized, double-blind, placebo-controlled phase 2 ARGO trial. Ann Rheum Dis. 2024;83(Suppl 1):154–5.

Article  Google Scholar 

Klint S, Feldwisch J, Gudmundsdotter L, et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023;15(1):2209920.

Article  PubMed  PubMed Central  Google Scholar 

Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1): e004062.

Article  PubMed  PubMed Central  Google Scholar 

Furst DE, Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):135.

Article  PubMed  PubMed Central  Google Scholar 

Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med (Lausanne). 2021;8:723944.

Article  PubMed  Google Scholar 

Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946–54.

Article  CAS  PubMed  Google Scholar 

Bennett AN, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413–8.

Article  CAS  PubMed  Google Scholar 

Dougados M, Sepriano A, Molto A, et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis. 2017;76(11):1823–8.

Article  PubMed  Google Scholar 

Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410–6.

Article  PubMed  PubMed Central  Google Scholar 

Marques ML, Ramiro S, van Lunteren M, et al. Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis. 2024;83(5):589–98.

Article  CAS  PubMed  Google Scholar 

Simon D, Tascilar K, Kleyer A, et al. Association of structural entheseal lesions with an increased risk of progression from psoriasis to psoriatic arthritis. Arthritis Rheumatol. 2022;74(2):253–62.

Article  PubMed  Google Scholar 

Simon D, Faustini F, Kleyer A, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis. 2016;75(4):660–6.

Article  CAS  PubMed  Google Scholar 

Liphardt AM, Manger E, Liehr S, et al. Similar impact of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function. ACR Open Rheumatol. 2020;2(12):734–40.

Article  PubMed  PubMed Central  Google Scholar 

Finzel S, Kraus S, Schmidt S, et al. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Ann Rheum Dis. 2013;72(7):1176–81.

Article  CAS  PubMed  Google Scholar 

Simon D, Kleyer A, Bayat S, et al. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Res Ther. 2019;21(1):162.

Article  PubMed  PubMed Central  Google Scholar 

Noversa de Sousa R, Tascilar K, Corte G, et al. Metabolic and molecular imaging in inflammatory arthritis. RMD Open. 2024;10(1):e003880.

Article  PubMed  PubMed Central  Google Scholar 

Tascilar K, Fagni F, Kleyer A, et al. Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography. Rheumatology (Oxford). 2023;62(2):841–9.

Article